<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098628</url>
  </required_header>
  <id_info>
    <org_study_id>HREC36027</org_study_id>
    <nct_id>NCT03098628</nct_id>
  </id_info>
  <brief_title>Trial of Simplified Pneumococcal Vaccination in Vietnam II</brief_title>
  <acronym>VPTII</acronym>
  <official_title>Trial of Simplified Pneumococcal Vaccination in Vietnam II: The Herd Immunity Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pasteur Institute, Ho Chi Minh City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-blind, open-label, randomised controlled trial with five groups. There are&#xD;
      four different Pneumococcal Conjugate Vaccine (PCV) schedules to be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-blind, open-label, randomised controlled trial with five groups. There are&#xD;
      four different PCV schedules to be evaluated: a 0+1 schedule of PCV10 at 12 months of age&#xD;
      (Group V), a 0+1 schedule of PCV13 at 12 months of age (Group W), a 1+1 schedule of PCV10 at&#xD;
      2 and 12 months of age (Group X), and a 1+1 schedule of PCV13 at 2 and 12 months of age&#xD;
      (Group Y); along with a control group that receives a dose of PCV10 at 24 months of age&#xD;
      (Group Z). Additionally, all participants will receive four doses of Infanrix-hexa at 2, 3, 4&#xD;
      and 18 months of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 8, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single-blind, open-label, randomised controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This is a single-blind, open-label, randomised trial, with laboratory staff blinded to study group allocation as all the outcome measures that address the study objectives are laboratory based. Laboratory samples will be labelled with a unique trial identification number that does not identify the study group. Given the different timing of the vaccine schedules in the different study arms, the study nurses, vaccine administrators and participants will not be blinded to the study group allocation of each infant.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Carriage of Vaccine Type pneumococci</measure>
    <time_frame>12 months post vaccination, i.e. 24 months of age</time_frame>
    <description>Evaluate the effect of a 0+1 PCV schedule administered at 12 months of age on Nasopharngeal Carrige (NP) carriage during the first two years of life, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carriage of Vaccine Type pneumococci</measure>
    <time_frame>12 months post last vaccination, i.e. 24 months of age</time_frame>
    <description>Evaluate the effect of a 1+1 PCV schedule administered at 2 and 12 months of age on NP carriage during the first two years of life, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunology sub-study</measure>
    <time_frame>12 months post vaccination, i.e. 24 months of age</time_frame>
    <description>i) To evaluate the immune responses to a 0+1 PCV schedule at 12 months of age, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology sub-study</measure>
    <time_frame>12 months post last vaccination, i.e. 24 months of age</time_frame>
    <description>ii) To evaluate the immune responses to a 1+1 PCV schedule at 2 and 12 months of age, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls;</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2501</enrollment>
  <condition>Pneumococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>V - PCV10 vaccine, 0+1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCV10, 0+1 schedule. PCV vaccine at 12 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>W - PCV13 vaccine, 0+1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCV13 in 0+1 schedule. PCV vaccine at 12 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X - PCV10 vaccine, 1+1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Y - PCV13 vaccine, 1+1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z - Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group. PCV vaccine given at end of study (24 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV Vaccine</intervention_name>
    <description>PCV vaccination</description>
    <arm_group_label>V - PCV10 vaccine, 0+1</arm_group_label>
    <arm_group_label>W - PCV13 vaccine, 0+1</arm_group_label>
    <arm_group_label>X - PCV10 vaccine, 1+1</arm_group_label>
    <arm_group_label>Y - PCV13 vaccine, 1+1</arm_group_label>
    <arm_group_label>Z - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 2 months and 2 months plus 2 weeks;&#xD;
&#xD;
          -  No significant maternal or perinatal history;&#xD;
&#xD;
          -  Born at or after 36 weeks gestation;&#xD;
&#xD;
          -  Written and signed informed consent from parent/legal guardian;&#xD;
&#xD;
          -  Lives within approximately 30 minutes of the commune health centre;&#xD;
&#xD;
          -  Family anticipates living in the study area for the next 22 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to any component of the vaccine;&#xD;
&#xD;
          -  Allergic reaction or anaphylactic reaction to any previous vaccine;&#xD;
&#xD;
          -  Known immunodeficiency disorder;&#xD;
&#xD;
          -  Known HIV-infected mother;&#xD;
&#xD;
          -  Known thrombocytopenia or coagulation disorder;&#xD;
&#xD;
          -  Administration or planned administration of any immunoglobulin or blood product since&#xD;
             birth;&#xD;
&#xD;
          -  Severe birth defect requiring ongoing medical care;&#xD;
&#xD;
          -  Chronic or progressive disease;&#xD;
&#xD;
          -  Seizure disorder;&#xD;
&#xD;
          -  History of severe illness;&#xD;
&#xD;
          -  Receipt of any 2 month vaccines through the Expanded Programme of Immunization (EPI)&#xD;
             program;&#xD;
&#xD;
          -  Family plans on giving the infant Quinvaxem (DTP-Hib-HBV).&#xD;
&#xD;
        Additionally, enrolment will be deferred and infants asked to return to the health centre&#xD;
        one week later for reassessment if they have at least one of the following deferral&#xD;
        criteria:&#xD;
&#xD;
          -  Axillary temperature ≥37.5°C or ≤35.5°C;&#xD;
&#xD;
          -  Acute infection, especially bacterial;&#xD;
&#xD;
          -  Oral administration of corticoid therapy in past 14 days; or&#xD;
&#xD;
          -  Any of the following symptoms that interfere with normal activities: crying more than&#xD;
             usual, sleeping more than usual, or loss of appetite.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Mulholland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Childrens Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nguyen Vu Thuong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pasteur Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pasteur Institute</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

